Five-Year Follow-Up of Early Lisuride and Levodopa Combination Therapy versus Levodopa Monotherapy in de novo Parkinson’s DiseaseAllain H.a · Destée A.b · Petit H.b · Patay M.c · Schück S.a · Bentué-Ferrer D.a · Le Cavorzin P.a
aLaboratoire de Pharmacologie Expérimentale et Clinique et Service de Neurologie, Faculté de Médecine, Université de Rennes I, Rennes, bClinique Neurologique, Hôpital Roger Salengro, Lille, and cLaboratoire Schering S.A., Lys-Les-Lannoy, France
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
The value of an early initial coadministration of levodopa (L-dopa) and lisuride in Parkinson’s disease was the main goal of the present study. Eighty-two patients with recently diagnosed idiopathic Parkinson’s disease were randomized into two groups for treatment with L-dopa alone or L-dopa + lisuride. The trial was double-blinded for the first year and open for the following 4 years. Selegiline (10 mg/day b.i.d.) was added in both groups at the end of the first year. Outcome measures were evolution of L-dopa dosage and Unified Parkinson’s Disease Rating Scale scores and subscores, and incidence of motor complications. The dropout rate was higher in the L-dopa group (63.4%) than in the combination group. Motor improvement was better (p < 0.01) in the L-dopa + lisuride group. Expected motor complications were rare, moderate and equivalent in the two groups despite a difference in L-dopa dosage (446.7 vs. 387.5 mg/day). Long-term follow-up demonstrated the L-dopa-sparing effect of lisuride (average 1 mg/day), the beneficial effect of early combination therapy on motor status and the paucity of motor complications in both groups.
© 2000 S. Karger AG, Basel
- Rinne UK: Treatment of Parkinson’s disease: Problems with a progressing disease. J Neural Transm 1981;51:161–174.
- Quinn NP: Antiparkinsonian drugs today. Drugs 1984;28:236–262.
- Melamed E: Initiation of levodopa therapy in parkinsonian patients should be delayed until the advanced stages of the disease. Arch Neurol 1986;43:402–405.
- Lees AJ: L-dopa treatment and Parkinson’s disease. Q J Med 1986;59:535–547.
- Lesser RP, Fahn S, Snider SR, Cote LJ, Isgreen WP, Barret RE: Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 1979;29:1253–1260.
- Shaw KM, Lees AJ, Stern GM: The impact of treatment with levodopa on Parkinson’s disease. Q J Med 1980;49:283–293.
- Clarke CE: Does levodopa therapy delay death in Parkinson’s disease? A review of the evidence. Mov Disord 1995;10:250–256.
Leenders KL, Palmer AJ, Quinn NP, Clark JC, Firnan G, Garnett ES, Nahmias C, Jones T, Marsden CD: Brain dopamine metabolism in patients with Parkinson’s disease measured with positron emission tomography. J Neurosurg Psychiatry 1986;49:853–860.
- Bravi D, Mouradian MM, Roberts JW, Davis TL, Sohn YH, Chase TN: Wearing-off fluctuations in Parkinson’s disease: Contribution of post-synaptic mechanisms. Ann Neurol 1994;36:27–31.
- Walkinshaw G, Waters CM: Induction of apoptosis in catecholaminergic PC cells by L-dopa; implications for treatment of Parkinson’s disease. J Clin Invest 1995;95:2458–2464.
Fahn S: Is levodopa toxic? Neurology 1996;47(suppl 3):S184–S195.
- Cheng N, Maeda T, Kume T, Kaneko S, Kochiyama H, Akaike A, Goshima Y, Misu Y: Differential neurotoxicity induced by L-dopa and dopamine in cultured striatal neurons. Brain Res 1996;743:278–283.
Fahn S: Levodopa-induced neurotoxicity. Does it represent a problem for the treatment of Parkinson’s disease? CNS Drugs 1997;8:376–393.
Marsden CD, Fahn S: Problems in Parkinson’s disease and other akinetic-rigid syndroms; in Marsden CD, Fahn S (eds): Movement Disorders 2. London, Butterworths & Co, 1987, pp 65–72.
- Rinne UK: Early combination of bromocriptine and levodopa in the treatment of Parkinson’s disease: A 5-year follow up. Neurology 1987;37:826–828.
- Vermersch P, Fondarai J, Petit H: Etude randomisée sur une année de l’association précoce L-dopa/lisuride dans la maladie de Parkinson. Thérapie 1991;46:481–486.
Fahn S, Elton RL, Members of the UPDRS Development Committee: Unified Parkinson’s Disease Rating Scale; in Fahn S, Marsden CD, Calne DB, Goldstein M (eds): Recent Development in Parkinson’s Disease. Florham Park, Mac Millan Healthcare Information 1987, vol 2, pp 153–163.
- Dangoumeau J, Evreux JC, Jouglard J: Méthode d’imputabilité des effets indésirables des médicaments. Thérapie 1978;33:373–381.
- Rinne UK: Lisuride, a dopamine agonist in the treatment of early Parkinson’s disease. Neurology 1989;39:336–339.
- Lees AJ: Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson’s disease. Parkinson’s Disease Research Group of the United Kingdom. BMJ 1995;311:1602–1607.
Destée A, Defèbvre L, Fondarai J, the French Lisuride Collaborative Group: Early combination of lisuride and levodopa in the treatment of Parkinson’s disease. Comparison with levodopa alone during a double blind then open trial: A 3 years follow-up. J Neurol 1996;243(suppl 2):S79 (abstract).
- Montastruc JL, Rascol O, Senard JM, Rascol A: A randomized controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson’s disease: A five year follow up. J Neurol Neurosurg Psychiatry 1994;57:1034–1038.
- Hely MA, Morris JG, Reid WG, O’Sullivan DJ, Williamson PM, Rail D, Broe GA, Margrie S: The Sydney multicenter study of Parkinson’s disease: A randomized prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry 1994;57:903–910.
- Weiner WJ, Factor SA, Sanchez-Ramos JR, Singer C, Sheldon C, Cornelius L, Ingenito A: Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson’s disease. Neurology 1993;43:21–27.
- Bergamasco B, Benna P, Scarzella L: Long-term bromocriptine treatment of de novo patients with Parkinson’s disease. A seven-year follow-up. Acta Neurol Scand 1990;81:383–387.
Stocchi F, Ruggieri S, Antonini A, Baronti F, Brughitta G, Bellantuono P, Bravi D, Agnoli A: Subcutaneous lisuride infusion in Parkinson’s disease: Clinical results using different modes of administration. J Neural Transm 1988;27(suppl):27–33.
- Lewitt PA, Gopinathan G, Ward CD, Sanes JN, Dambrosia JM, Durso R, Calne DB: Lisuride versus bromocriptine treatment in Parkinson’s disease: A double blind study. Neurology 1982;32:69–72.
- Gopinathan G, Teravainen H, Dambrosia JM, Ward CD, Sanes JN, Stuart WK, Evarts EV, Calne DB: Lisuride in parkinsonism. Neurology 1981;31:371–376.
- Parkinson Study Group: Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP subjects not requiring levodopa. Ann Neurol 1996;39:29–36.
- Parkinson Study Group: Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP patients requiring Levodopa. Ann Neurol 1996;39:37–45.
Bentué-Ferrer D, Ménard G, Allain H: Monoamine oxidase B inhibitors: Current status and future potential. CNS Drugs 1996;6:217–236.
Lange KW, Rausch WD, Gsell W, Naumann M, Oestreicher E, Riederer P: Neuroprotection by dopamine agonists. J Neural Transm 1994;43(suppl):183–201.
- Ogawa N, Haba K, Yoshikawa N, Kawata M, Sato H: Effects of lisuride hydrogen maleate on ischemia-induced depletion of brain acetylcholine levels in gerbils. Clin Ther 1989;11:241–246.
- Caldwell MA, Reymann JM, Bentué-Ferrer D, Allain H, Leonard B: The dopamine agonists lisuride and piribedil protect against behavioural and histological changes following 4-vessel occlusion in the rat. Neuropsychobiology 1996;34:117–124.
- Caldwell MA, Reymann JM, Allain H, Leonard BE, Bentué-Ferrer D: Lisuride prevents learning and memory impairment and attenuates the increase in extracellular dopamine induced by transient global ischemia in rats. Brain Res 1997;771:305–318.
- Hall ED, Andrus PK, Oostven JA, Althaus JS, von Voigtlander PF: Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against post-ischemic or methamphetamine-induced degeneration of nigro-striatal neurons. Brain Res 1996;742:80–88.
- O’Neill MJ, Hicks CA, Ward MA, Reymann JM, Allain H, Bentué-Ferrer D: D2 agonists protect against ischaemia-induced hippocampal neurodegeneration in global cerebral ischaemia. Eur J Pharmacol 1998;352:37–46.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.